![1]() - News- EVALI readmissions and deaths prompt guideline change- December 23, 2019- Approximately one in seven deaths from vaping-related lung injuries have occurred after discharge. 
- News- Vitamin E acetate confirmed as likely source of EVALI- December 23, 2019- Most patients with vaping-associated lung problems reported THC or nicotine vaping within 90 days of illness onset. 
![1]() - News- A novel communication framework for inpatient pain management- December 20, 2019- Spend adequate time to fully visit the patients’ history as it relates to their current pain complaints. 
![1]() - News- FDA warns gabapentin, pregabalin may cause serious breathing problems- December 19, 2019- The drugs increase the risk of respiratory depression when used with central nervous system depressants or in patients with lung problems, according to a Dec. 19 drug safety alert. 
![1]() - News- ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding- December 16, 2019- LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib. 
![1]() - News- Improving sepsis-related outcomes- December 12, 2019- A dedicated quality improvement project shows results. 
![1]() - News- New ASH guideline: VTE prophylaxis after major surgery- December 12, 2019- ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the American Society of Hematology. 
![1]() - News- Cardiac arrhythmia heightens mortality risk during epilepsy hospitalizations- December 11, 2019- BALTIMORE – A secondary diagnosis of apnea is not independently associated with increased odds of death, however. 
![1]() - News- EVALI outbreak ongoing, but new cases decline- December 9, 2019- Since the week of Sept. 15, 2019, hospitalized cases of EVALI have steadily declined. 
![1]() - News- Genetic test stratified AFib patients with low CHA2DS2-VASc scores- December 9, 2019- A 32-locus genetic test classified AFib patients with low CHA2DS2-VASc scores into high– and low–stroke-risk subgroups. 








